Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Antibody-drug conjugates (ADCs) are reshaping NSCLC treatment, but experts say the next breakthroughs won't come from finding new targets — they'll come from better payloads, smarter dosing, and sharper patient selection. New data from multiple phase 2 and 3 trials show promising efficacy and improved tolerability with next-generation ADCs, while also revealing the limits of current biomarker strategies like IHC.
Antibody-drug conjugates (ADCs) have become a cornerstone of non-small cell lung cancer (NSCLC) treatment, but the field may be hitting a ceiling — and the path forward isn't just about finding new targets. At the 44th Annual Chemotherapy Foundation Symposium, Dana-Farber's Dr. Alissa Cooper argued that payload innovation, linker design, and smarter patient selection matter more than target novelty, especially since most current ADCs share the same topoisomerase I inhibitor warhead.
New trial data back this up. Sacituzumab tirumotecan (sac-TMT) outperformed platinum doublet chemo in EGFR-mutated NSCLC post-TKI progression, with a median OS of 25.9 vs. 17.4 months and zero treatment discontinuations due to adverse events. In the frontline setting, sac-TMT plus pembrolizumab delivered a median PFS of 15.0 vs. 5.7 months in PD-L1–negative patients. Meanwhile, next-gen HER2- and MET-directed ADCs showed high response rates with low ILD rates, pointing to a widening therapeutic window. On the flip side, sigvotatug vedotin (IB6-directed) failed its phase 3 OS endpoint, and IHC expression showed no clear link to activity — a cautionary tale for biomarker strategy.
Key Takeaways:
Why it matters: With most ADCs sharing the same payload class, sequencing them risks diminishing returns. Diversifying payload mechanisms, rethinking dosing strategies, and building robust biomarker frameworks are now essential to unlocking the full potential of ADCs for NSCLC patients.